Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 4, 2004, Pages 1233-1240

  Siemann, Dietmar W ^b   Shi, Wenyin ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antiangiogenic therapy; Vascular disrupting therapy; Vascular targeting; ZD6126; ZD6474

Indexed keywords

ANTITUMOR EFFICACY; HUMAN RENAL CELL CARCINOMA; TUMOR GROWTH; VESSEL FORMATION;

BLOOD VESSELS; CELLS; DRUG DOSAGE; MATHEMATICAL MODELS; TUMORS;

PATIENT TREATMENT;

ANGIOGENESIS INHIBITOR; N ACETYLCOLCHINOL PHOSPHATE; VANDETANIB; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; KAPOSI SARCOMA; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PIPERIDINES; QUINAZOLINES; SARCOMA, KAPOSI;

EID: 7444259131     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.08.002     Document Type: Article

References (54)

1. J. Denekamp Endothelial cell attack as a novel approach to cancer therapy Cancer Top 6 1986 6 8
2. J. Denekamp Vascular attack as a therapeutic strategy for cancer Cancer Metast Rev 9 1991 267 282
3. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
4. L.M. Ellis, W. Liu, S.A. Ahmad Overview of angiogenesis: Biologic implications for antiangiogenic therapy Semin Oncol 28 2001 94 9104
5. D.W. Siemann Vascular targeting agents Horizons Cancer Therapeut 3 2002 4 15
6. Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for cancer treatment. Cancer 2004;100:2491-2499.
7. P.E. Thorpe Vascular targeting agents as cancer therapeutics Clin Cancer Res 10 2004 415 427
8. N. Ferrara, S. Bunting Vascular endothelial growth factor, a specific regulator of angiogenesis Curr Opin Nephrol Hypertens 5 1996 35 44
9. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803
10. N. Weidner, J. Folkman, F. Pozza Tumor angiogenesisA new significant independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 84 1992 1875 1887
11. K. Maeda, Y.S. Chung, Y. Ogawa Prognostic value of vascular endothelial growth factor expression in gastric carcinoma Cancer 77 1996 858 863
12. L.F. Hennequin, A.P. Thomas, C. Johnstone Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors J Med Chem 42 1999 5369 5389
13. F. Carlomagno, D. Vitagliano, T. Guida ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 2002 7284 7290
14. S.R. Wedge, D.J. Ogilvie, M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
15. S.M. Galbraith, D.J. Chaplin, F. Lee Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo Anticancer Res 21 2001 93 9102
16. C. Kanthou, G.M. Tozer The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood 99 2002 2060 2069
17. D.J. Chaplin, G.R. Pettit, S.A. Hill Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate Anticancer Res 19 1999 189 195
18. A.M. Rojiani, L. Li, L. Rise Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma Acta Oncol 41 2002 98 9105
19. D.C. Blakey, F.R. Westwood, M. Walker Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models Clin Cancer Res 8 2002 1974 1983
20. G. Micheletti, M. Poli, P. Borsotti Vascular-targeting activity of ZD6126, a novel tubulin-binding agent Cancer Res 63 2003 1534 1537
21. D.W. Siemann, A.M. Rojiani Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 53 2002 164 171
22. D.W. Siemann, A.M. Rojiani Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 54 2002 1512 1517
23. P.D. Davis, G.J. Dougherty, D.C. Blakey ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 2002 7247 7253
24. D. Ausprunk, J. Folkman Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis Microvasc Res 14 1977 53 65
25. J. Folkman How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46 1986 467 473
26. P. Hahnfeldt, D. Panigrahy, J. Folkman Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy Cancer Res 59 1999 4770 4775
27. M.A. Konerding, A.J. Miodonski, A. Lametschwandtner Microvascular corrosion casting in the study of tumor vascularity: A review Scanning Microsc 9 1995 1233 1244
28. M.A. Konerding, C. van Ackern, E. Fait Morphological aspects of tumor angiogenesis and microcirculation M. Molls P. Vaupel Blood perfusion and microenvironment of human tumors 2002 Springer Berlin 5 17
29. M.R. Horsman, J. Overgaard The oxygen effect and the tumour microenvironment G.G. Steel Basic clinical radiobiology for radiation oncologists 3rd ed 2002 Edward Arnold London 158 168
30. D.J. Chaplin, M.R. Horsman, M.J. Trotter Therapeutic significance of microenviroment factors M. Molls P. Vaupel Medical radiology: Blood perfusion and microenviroment of human tumours 1998 Springer-Verlag Heidelberg 133 143
31. A.J. Giaccia Hypoxic stress proteins: Survival of the fittest Semin Radiat Oncol 6 1996 46 58
32. T. Graeber, C. Osmanian, T. Jacks Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors Nature 379 1996 88 91
33. K. De Jaeger, M.C. Kavanagh, R.P. Hill Relationship of hypoxia to metastatic ability in rodent tumours Br J Cancer 84 2001 1280 1285
34. S.D. Young, R.S. Marshall, R.P. Hill Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells Proc Natl Acad Sci USA 85 1988 9533 9537
35. J. Denekamp Vascular attack as a therapeutic strategy for cancer Cancer Met Rev 9 1990 267 282
36. H.J. Bloemendal, T. Logtenberg, E.E. Voest New strategies in anti-vascular cancer therapy Eur J Clin Invest 29 1999 802 809
37. I.J. Fidler, L.M. Ellis The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 79 1994 185 188
38. M.S. O'Reilly, L. Holmgren, Y. Shing Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328
39. S.S. Yoon, H. Eto, C.M. Lin Mouse endostatin inhibits the formation of lung and liver metastases Cancer Res 59 1999 6251 6256
40. F. Liao, Y. Li, W. O'Connor Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis Cancer Res 60 2000 6805 6810
41. W. Landuyt, B. Ahmed, S. Nuyts In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment Int J Radiat Oncol Biol Phys 49 2001 443 450
42. D.W. Siemann, W. Shi Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy Semin Radiat Oncol 13 2003 53 61
43. L.M. Ellis, Y. Takahashi, W. Liu Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications Oncologist 5 Suppl. 1 2000 11 15
44. B.A. Teicher, S.A. Holden, G. Ara Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents Int J Cancer 57 1994 920 925
45. B.A. Teicher, S.A. Holden, G. Ara Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy Int J Cancer 61 1995 732 737
46. C. Hess, V. Vuong, I. Hegyi Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth Br J Cancer 85 2001 2010 2016
47. K. Grosios, P.M. Loadman, D.J. Swaine Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma Anticancer Res 20 2000 229 233
48. S.V. Kozin, Y. Boucher, D.J. Hicklin Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res 61 2001 39 44
49. P. Wachsberger, R. Burd, A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction Clin Cancer Res 9 2003 1957 1971
50. C.J. Lash, A.E. Li, M. Rutland Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs Br J Cancer 78 1998 439 445
51. D.W. Siemann, E. Mercer, S.E. Lepler Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int J Cancer 99 2002 1 6
52. Siemann DW, Horsman MR. Targeting the tumor vasculature: A strategy to improve radiation therapy. Expert Rev Anticancer Ther 2004;4:89-95.
53. L. Li, A.M. Rojiani, D.W. Siemann Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma Acta Oncol 41 2002 91 97
54. S.R. Wedge, J. Kendrew, D.J. Ogilvie Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response [Abstract] Proc Am Assoc Cancer Res 43 2002 1081